Phillip J. Koo, MD

Banner MD Anderson Cancer Center

Phoenix, Arizona

Phillip J. Koo, MD, is the Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology and the American Board of Nuclear Medicine. Dr. Koo is an active member of multiple societies and has served as the Chair of Nuclear Medicine for the RSNA Scientific Program Committee, Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Chair of the Prostate Cancer Working Group at the SNMMI. Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, the European Journal of Nuclear Medicine and Molecular Imaging, Urology, and the Journal of the American College of Radiology.

Disclosures:

Articles by Phillip J. Koo, MD

Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Posted by Phillip J. Koo, MD | Jul 2018

Phillip J. Koo, MD, Chair of the Prostate Cancer Outreach Working Group, discusses advances in nuclear medicine and imaging, basic concepts of the theranostic approach, and controversies in this field. Following Dr. Koo’s discussion of the current state of nuclear medicine, Susan F. Slovin, MD, PhD, discusses the three iterations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR).

Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223

Posted by Phillip J. Koo, MD | Apr 2018

Philip J. Koo, MD, describes the mechanism of action of Radium-223 in prostate cancer treatment, options for combining and layering Radium-223 with other drugs, and how the field of radiation is evolving. He also addresses the controversial ERA 223 trial results.

Imaging of Prostate Cancer Patients Following Definitive Therapy

Posted by Phillip J. Koo, MD | Feb 2018

Dr. Phillip J. Koo, MD, discusses advanced tools such as multi-parametric MRI and PET/CT for prostate cancer imaging, and how they outperform traditional, previously available methods.

Therapeutic Radiopharmaceuticals and the Emergence of Theranostics

Posted by Phillip J. Koo, MD | Jan 2018

Dr. Phillip J. Koo, MD, discusses the use of radiopharmaceuticals in prostate cancer treatment, as well as the area of theranostics. He goes into detail on the process of choosing these radiopharmaceuticals and trying to determine the best ones to use in various situations in regards to prostate cancer.

Timing and Optimization of Radium 223 in CRPC

Posted by Phillip J. Koo, MD | Jan 2018

Dr. Phillip J. Koo, MD, discusses the appropriate timing of radium 223 treatments in castration resistant prostate cancer patients, the best approaches to therapeutic layering, and the importance of recognizing bone metastasis when making these therapeutic decisions.

Phillip J. Koo, MD

Banner MD Anderson Cancer Center

Phoenix, Arizona

Articles by Phillip J. Koo, MD

Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223

Imaging of Prostate Cancer Patients Following Definitive Therapy

Therapeutic Radiopharmaceuticals and the Emergence of Theranostics

Timing and Optimization of Radium 223 in CRPC

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Phillip J. Koo, MD

Banner MD Anderson Cancer Center

Phoenix, Arizona

Articles by Phillip J. Koo, MD

Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223

Imaging of Prostate Cancer Patients Following Definitive Therapy

Therapeutic Radiopharmaceuticals and the Emergence of Theranostics

Timing and Optimization of Radium 223 in CRPC

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses